Aion Therapeutic Past Earnings Performance
Past criteria checks 0/6
Aion Therapeutic's earnings have been declining at an average annual rate of -1.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 102.8% per year.
Key information
-1.4%
Earnings growth rate
38.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 102.8% |
| Return on equity | n/a |
| Net Margin | -788.9% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Aion Therapeutic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 1 | -6 | 2 | 0 |
| 30 Apr 24 | 0 | -6 | 1 | 0 |
| 31 Jan 24 | 0 | -1 | 1 | 0 |
| 31 Oct 23 | 0 | -1 | 1 | 0 |
| 31 Jul 23 | 0 | -1 | 1 | 0 |
| 30 Apr 23 | 0 | 0 | 1 | 0 |
| 31 Jan 23 | 0 | -2 | 1 | 0 |
| 31 Oct 22 | 0 | -2 | 1 | 0 |
| 31 Jul 22 | 0 | -3 | 1 | 1 |
| 30 Apr 22 | 0 | -4 | 1 | 1 |
| 31 Jan 22 | 0 | -7 | 2 | 1 |
| 31 Oct 21 | 0 | -8 | 2 | 0 |
| 31 Jul 21 | 0 | -8 | 2 | 0 |
| 30 Apr 21 | 0 | -8 | 2 | 0 |
| 31 Jan 21 | 0 | -3 | 2 | 0 |
| 31 Oct 20 | 0 | -2 | 1 | 0 |
| 31 Jul 20 | 0 | -1 | 1 | 0 |
| 30 Apr 20 | 0 | -1 | 1 | 0 |
| 31 Jan 20 | 0 | -1 | 1 | 0 |
| 31 Oct 19 | 0 | -1 | 1 | 0 |
| 31 Jul 19 | 0 | -5 | 2 | 0 |
| 30 Apr 19 | 0 | -5 | 1 | 0 |
| 31 Jan 19 | 0 | -6 | 3 | 0 |
Quality Earnings: ANTC.F is currently unprofitable.
Growing Profit Margin: ANTC.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANTC.F is unprofitable, and losses have increased over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare ANTC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANTC.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ANTC.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.